The anti-colorectal cancer effect and metabolites of Agrimonia pilosa Ledeb.

Autor: Wang L; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Chen Q; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Song H; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Xing W; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Shi J; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Li Y; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Lv Y; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Wang Z; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China., Chen J; School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China., Zhao W; School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China. Electronic address: zwhua@ccmu.edu.cn.
Jazyk: angličtina
Zdroj: Journal of ethnopharmacology [J Ethnopharmacol] 2024 Jul 15; Vol. 329, pp. 118146. Date of Electronic Publication: 2024 Apr 09.
DOI: 10.1016/j.jep.2024.118146
Abstrakt: Ethnopharmacological Relevance: Agrimonia pilosa Ledeb. (Rosaceae, A. pilosa) has been used in traditional medicine in China, Japan, Korea, and other Asian countries for treatment of acute and chronic enteritis and diarrhea. Secondary metabolites have been isolated and tested for biological activities. It remains unclear in terms of its potential components of anti-colorectal cancer properties.
Aim of the Study: The study aimed to how extracts from A. pilosa and their components influenced tumor microenvironment and the colorectal tumor growth in vivo on AOM/DSS induced colorectal cancer mice, the metabolites of A. pilosa was also been studied.
Materials and Methods: Different methods have been used to extract different parts of A. pilosa. And the anti-proliferation effect of these extracts on colon cancer cells have been tested. The components of A. pilosa and its metabolites in vivo were analyzed by UPLC-QTOF-MS/MS. The anti-colorectal cancer (CRC) effects of A. pilosa and its components in vivo were studied on AOM/DSS induced CRC mice. The effects of constituents of A. pilosa on the composition of immune cells in tumor microenvironment (TME) were analyzed by flow cytometry. 16 S rDNA technology was used to analyze the effect of administration on the composition of intestinal microflora. Pathological section staining was used to compare the morphological changes and molecular expression of intestinal tissue in different groups.
Results: The constituent exists in root of A. pilosa showed the strongest anti-proliferation ability on colon cancer cells in vitro. The extract from the root of A. pilosa could attenuate the occurrence of colorectal tumors induced by AOM/DSS in a concentration-dependent manner. Administration of the extract from the root of A. pilosa could affect the proportion of γδT cells, tumor associated macrophages and myeloid derived suppressor cells in TME, increasing the proportion of anti-tumor immune cells and decrease the immunosuppressive cells in the TME to promote the anti-tumor immune response. The administration of the extract adjusted the composition of gut microbiota and its components Agrimoniin and Agrimonolide-6-o-glucoside showed the strongest anti-CRC effect in vivo with adjusting the gut microbiota differently.
Conclusions: The extract from root of A. pilosa showed anti-colorectal cancer effects in vivo and in vitro, affecting the composition of gut microbiota and the anti-tumor immune response. Within all components of A. pilosa, Agrimoniin and Agrimonolide-6-o-glucoside showed remarkable anti-CRC efficiency in vivo and in vitro. Besides, the metabolites of extract from root of A. pilosa in gastrointestinal tract mainly composed of two parts: Agrimonolide-related metabolites and Urolithins. The extract from root of A. pilosa could contribute to potential drugs for assisting clinical anti-colon cancer therapy.
Competing Interests: Declaration of competing interest The authors have no conflict of interest.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: